

CURRICULUM VITAE

Michael Gregory Kurilla, MD-PhD

CONTACT INFORMATION

michael.kurilla@nih.gov

O: (301) 435-0178

M: (302) 354-2351

CURRENT POSITION (since 2017)

**Director, Division of Clinical Innovation, National Center for Advancing
Translational Sciences, NIH**

EDUCATION AND TRAINING

Harvard Medical School, Department of Microbiology and Molecular Genetics,
Postdoctoral Research Fellow, 1987 - 1991 (Elliott Kieff laboratory)

Brigham and Women's Hospital, Department of Pathology, Pathology Residency,
1985 - 1989 (Dr. Ramzi Cotran, chairman)

Duke University, Durham, North Carolina, **M.D.**, 1985, School of Medicine

Duke University, Durham, North Carolina, **Ph.D.**, 1984, Department of Microbiology
and Immunology (Dr. Jack Keene, thesis advisor)

California Institute of Technology, Pasadena, California, **B.S.**, 1979, Chemistry (Dr.
Vincent McKoy, advisor)

PAST PROFESSIONAL EXPERIENCE

Director, Office of BioDefense, Research Resources, and Translational Research
(Note: name was officially changed from Office of BioDefense Research Affairs
in 2013), DMID, NIAID, NIH (2005-2017)

Associate Director, BioDefense Product Development, NIAID, NIH (2005-2017)

Medical Officer, Tuberculosis, Leprosy, and other Mycobacterial Diseases, DMID,
NIAID, NIH (2003-2005)

Associate Director, Infectious Diseases, Wyeth (2002)

Director, Antimicrobials, Dupont Pharmaceuticals Inc. (2001)

Associate Director, Antimicrobials, Dupont Pharmaceuticals Inc. (1998 - 2001)

Associate Director, Molecular Pathology Laboratory, University of Virginia Health
Sciences Center (1996 - 1998)

Associate Director, Clinical Microbiology, University of Virginia Health Sciences Center
(1994 - 1998)

Assistant Professor, Department of Microbiology, University of Virginia (1992 - 1998)

Member, Cancer Center, University of Virginia (1991 - 1998)

Associate Director, DNA Molecular Pathology Lab, University of Virginia Health Sciences Center (1991 - 1993)
Assistant Professor, Department of Pathology, University of Virginia (1991 - 1998)
Research Fellow, Department of Microbiology and Molecular Genetics, Harvard Medical School (1987 - 1991)
Research Fellow, Department of Medicine, Brigham and Women's Hospital (1987 - 1991)
Clinical Fellow in Pathology, Harvard Medical School (1985 - 1987)
Pathology Resident, Brigham and Women's Hospital, Boston, Mass. (1985 - 1989)

ACADEMIC AND PROFESSIONAL HONORS

NIAID Special Act Awards (2017, 2016, 2015, 2012, 2008, 2006, 2005)
NIAID Merit Awards (2016, 2015x3, 2011x2, 2009, 2008x2, 2006)
NIH Director's Awards (2015, 2012, 2007x2)
HHS Secretary's Award for Distinguished Service (2013)
Public Health Achievement, FDA (2012)
NIH OD Merit Award (2008)
DuPont Pharmaceuticals Corp EHS Pioneer Award (2000)
Lucille P. Markey Scholar (1989 - 1996)
Life Sciences Research Foundation Fellow (1987 - 1989)
Richard O. Burns Research Award, Department of Microbiology and Immunology, Duke University (1984)
Medical Scientist Training Program, Duke University (1979 - 1985, NIH - GM07171)
Summer Research Assistantship, Lawrence Livermore Laboratory (1979)
Graduation with Honors, California Institute of Technology (1979)
Department of Engineering and Applied Science Summer Research Grant, Yale University (1978)
National Science Foundation Undergraduate Research Grant, California Institute of Technology (1977)

SYMPOSIUM / CONFERENCE / WORKSHOP / MEETING / SESSION ORGANIZATION & PLANNING (since 2008)

Moderator, Plenary Session & Panel – Columbia University opioid Symposium: Building New Collaborations Towards New Solutions (2018)
Session Facilitator, WHO Consultation – Evaluating Therapeutics during Public Health Emergencies (2017)
Planning Committee, NIAID / PATH / CEPI / DBT-India Sponsored Chikungunya Vaccine Workshop (2017)
Planning Committee, Public Workshop: Current State and Further Development of Animal Models of Serious Infections cause by *Acinetobacter Baumannii* and *Pseudomonas Aeruginosa* (2017)
Moderator, Session: Vectors and Viruses, IDWeek 2016 (2016)
Chair, Medicines and Blood Products Session, WHO & Wellcome Trust Sponsored

Mosquito-borne viruses: can we build on commonalities to pre-empt the future?
Conference (2016)
Discussion Leader, AMR Public Funding R&D, Alexandria Summit Infectious Diseases
(2016)
Roundtable Facilitator, Medical Surge for Mass Casualty Infectious Disease Events,
Preparedness Leadership Council International (2016)
Planning Committee & Session Facilitator, USG Ebola Research Agenda (2016)
Planning Committee, IDWeek 2016 (2015-2016)
Planning Committee / Session Organizer, 2016 PHEMCE Stakeholders Workshop (2015)
Moderator, Symposium: MERS, Chikungunya, and Dengue: The Emergence Continues
& Session: Emerging Public Health Threats, IDWeek 2015 (2015)
Federal Partners Committee, Botulism Antitoxin Use and the Clinical Management of
Botulism (2015)
Co-Chair, NIAID, FDA, BARDA, DOD, and CDC Workshop, Immunology of Protection
from Ebola Virus Infection (2014)
Planning Committee, IDWeek 2015 (2014-2015)
Moderator, Session: Late Breaker Oral Abstracts, IDWeek 2014 (2014)
Planning Committee, NIH/FDA Workshop: The Development of New Antibacterial
Products Charting a Course for the Future (2014)
Planning Committee, IOM: Enabling Rapid Medical Countermeasure Response to
Emerging Threats (2014)
Planning Committee, IDWeek 2014 (2013-2014)
Steering Committee, Utilization Plan for Anthrax Medical Countermeasure Use in a Mass
Casualty Event (2013)
Scientific Program Committee, 6th Biennial China-U.S. Relations Conference (2013)
Steering Committee, Smallpox Vaccine Clinical Utilization Workshop (2013)
Planning Committee, IDWeek 2013 (2012-2013)
Co-Chair, Technical Symposium, 10th Annual Biodefense Vaccines & Therapeutics
Conference (2012)
Co-Chair, FDA/NIAID Public Workshop: The Development of Next-Generation
Smallpox Vaccines (2011)
Planning Committee, National BioDefense Science Board Public Engagement Workshop:
Vaccine to Protect Children from Anthrax (2011)
Planning Committee, Joint NIH-Industry Target Validation Workshop (2011)
Co-Chair, Developments in Biodefense Technology Platforms (2011)
Planning Committee, IOM Workshop: Advancing Regulatory Science for Medical
Countermeasure Development (2011)
Planning Committee, 5th Annual PHEMCE Stakeholders Workshop & BARDA Industry
Day (2011)
Co-Chair, FDA/NIAID/IDSA Public Workshop: Antibacterial Resistance and Diagnostic
Device and Drug Development Research for Bacterial Diseases (2010)
Co-Chair, Developments in Biodefense Technology Platforms (2010)
Planning Committee, IOM Workshop: The Public Health Emergency Medical
Countermeasures Enterprise: Innovative Strategies to Enhance Products from
Discovery through Approval (2010)
Planning Committee, PHEMCE Stakeholders Workshop (2009)

Co-Chair, Biodefense Vaccines Scientific Symposium (2008)

INVITED ORAL PRESENTATIONS (since 2009)

- Columbia University Opioid Symposium – Building New Collaborations Towards New Solutions: **“Research Update from the National Center for Advancing Translational Science”** (2018)
- “Un-Meeting” to Address the Opioid Crisis through Translational Science: **“Addressing the Opioid Epidemics through Translational Science”** (2018)
- 7th Annual Translational Science Symposium – Addiction Medicine 2018: Translational Science at the Cutting Edge: **“NCATS Perspectives”** (2018)
- FDA / NIAID Bacteriophage Therapy Scientific and Regulatory Issues Workshop: **“Closing Remarks”** (2017)
- Boston University School of Medicine, New England Infectious Diseases Laboratory: **“Infectious Disease Outbreak Response: Reactive, Proactive, Hyperactive, and Mostly Unattractive”** (2017)
- Public Health England: **“NIAID Portfolio: BioDefense and other Bothersome Infectious Diseases”** (2017)
- United Kingdom National Institute of Biological Standards and Controls: **“NIAID Portfolio: Public Health and Emerging Infectious Diseases”** (2017)
- NIAID Workshop PKPD for Development of Therapeutics against Bacterial Pathogens: **“Opening Remarks”** (2017)
- Wellcome Trust: **“NIAID Portfolio: Emerging, Submerging, and Scourging Infectious Disease”** (2017)
- Innovations in Infectious Disease Research: Challenges and Opportunities: **Keynote address – “Infectious Disease & Public Health: Reactive, Proactive, Hyperactive, and Somewhat Unattractive”** (2017)
- WHO Informal Consultation on options to improve regulatory preparedness to address public health emergencies: **“Lessons learned from Ebola and Zika on product development for therapeutics and biotherapeutics, including convalescent plasma”** (2017)
- National Academy of Medicine Workshop: Opportunities for the Future of Healthcare and Public Health Preparedness, Response, and Recovery: **“Keynote Panel Inspiring Advancement in Health and Public Health Preparedness Despite Challenges”** (2017)
- The Biology of Anthrax: **“Current and Future Anthrax Countermeasures: Where Can the Science Take Us?”** (2016)
- 8th International Symposium on Filoviruses & 58th ITM Colloquium: **“Lessons Learned for the Next Outbreak”** (2016)
- Bellagio Global Virome Project (GVP) Forum: **“Financial approaches and strategies for GVP (the ‘halo’ effect) Panel”** (2016)
- Vaccine Technology VI Conference (Opening Keynote Address): **“Vaccines: Reaching for Higher Branches after the Low Hanging Fruit has been Picked”** (2016)
- BIO International Convention: **“If You Can’t Beat ‘Em, Join ‘Em: Evolving Approaches to Tackle Resistant Pathogens Panel”** & **“Biotech Research**

- Ecosystem Session: From Lab to Patient”** (2016)
- Infocast 14th Annual Vaccines & Therapeutics: **“Current US Government Views on Biodefense”** (2016)
- North Carolina Central University Biomanufacturing Research Institute and Technology Enterprise: **“Product Development Capabilities for Infectious Diseases and Public Health”** (2016)
- Alliances and Incentives in the Era of Outbreaks, Sanford School of Public Policy, Duke University: **“Prerequisites Preferred for the Perfect Partnership”** (2016)
- World Vaccine Congress: **“Public / Private Partnership Panel”** (2016)
- Milken Institute Public Health Summit: **“Infectious Diseases: Staying One Step Ahead”** (2016)
- 11th Annual Non-Dilutive Funding Summit: **“Infectious Disease Product Enabling Opportunities with NIAID”** (2016)
- Morehouse College of Medicine: **“Enabling Product Development Efforts for Infectious Diseases and Public Health”** (2016)
- National Institute of Standards and Technology: **“NIAID BioDefense & Infectious Diseases Product Development”** (2015)
- Presidential Council of Advisors on Science and Technology: **“NIAID BioDefense R&D: Evolving with the Threat”** (2015)
- Pennsylvania Bio - Life Sciences Future: **“Vaccine Panel”** (2015)
- Parental Drug Association 10th Annual Global Conference on Pharmaceutical Microbiology: **“The NIH Perspective: The Science Behind Ebola and the Challenge in a Global Environment”** (2015)
- 23rd International Union of Biochemistry and Molecular Biology Congress & 44th Annual Meeting of the Brazilian Society for Biochemistry and Molecular Biology: **“Emerging Viral Diseases & Vaccines”** (2015)
- Bacteriophage Therapy: An Alternative Strategy to Combat Drug Resistance: **“Bacteriophage Therapy”** (2015)
- BIO International Conference: **“Ebola – Selected Lessons”** (2015)
- Atlantic Vaccine & Therapeutics Summit: **“NIAID Funding, Priorities, and Successes”** (2015)
- Phacilitate VAX 1-2-1: **“Redrawing the Roadmap for Vaccine Funding, Partnering, and Supply”** & **“Incentivizing R&D Innovation and the Uptake of Cutting Edge Technologies Worldwide”** (2015)
- Health and Human Services Chief Financial Officer Community Training: **“Ebola Response Panel”** (2015)
- National Academy of Sciences Annual Meeting: **“Ebola: Interventional Development”** (2015)
- 7th Annual NBL-RBL Network Meeting: **“Post Ebola: Filoviruses and other High Containment Agents”** (2015)
- National Foundation for Infectious Diseases Annual Conference on Vaccine Research: **“Ebola Vaccines in Development”** (2015)
- 7th International Symposium on Filoviruses: **“Roundtable Discussion with Funding Agencies”** (2015)
- Forum on Microbial Threats, National Academy of Sciences: **“The Response to the Ebola Outbreak: A View from the NIH”** (2015)

- Center for Strategic and International Studies: **“Relevant Issues for Ebola Diagnostics”** (2015)
- American Association for the Advancement of Science (AAAS) Annual Meeting: **“Every Outbreak is a Test: The Lessons Come After”** (2015)
- Darwin Week, University of Northern Iowa: **“Ebola Ebullition”** (2015)
- National Institute of General Medical Sciences: **“Ebola Virus Biology: Vaccines, Therapeutics, and Diagnostics”** (2014)
- Public Health Issues for Ebola: Modeling for Policy, BARDA/NIGMS: **“Genetic Sequencing of Ebola Virus: Implications for Diagnostics, Therapeutics, and Vaccines”** (2014)
- Biowatch Webinar, Department of Homeland Security: **“Development of Vaccinations”** (2014)
- WHO Consultation on Scientific and Regulatory Pathways for the Development, Approval and Use of Monoclonal Antibodies against Infectious Diseases, WHO/PAHO: **“Lessons Learnt from the Current Outbreak and Use of Zmapp”** (2014)
- 29th Annual Meeting of the Japanese Association for International Health: **“Innovation through Partnership”** (2014)
- NIAID Diagnostics & Therapeutics Workshop: **“Coordinated Development of Diagnostics & Therapeutics”** (2014)
- Consultation on Potential Ebola Therapies and Vaccines, WHO meeting: **“Overview of Lead Experimental Products and Product Specific Considerations”** (2014)
- Translational Science 2014: **“Vaccine Research & Development”** (2014)
- New Technologies, New Vaccines Conference: **“Vaccines & Vaccinations”** (2014)
- Centers for Disease and Control (CDC): **“NIAID BioDefense Portfolio”** (2014)
- One Med Forum: **“Non-Dilutive Financing – An Essential Channel in Maintaining R&D”** (2013)
- US Japan Biodefense Meeting: **“Enabling Anti-Infective Drug Product Efforts across the Development Spectrum”** (2013)
- 11th Annual Emerging Infectious Diseases and Biodefense Summit: **“Enabling Anti-Infective Drug Product Efforts”** (2013)
- World Vaccine Congress: **“Biodefense Vaccines – Overview”** (2013)
- RBL – NBL Biodefense Network Meeting: **“Current Opportunities and Future Trends at NIAID”** (2013)
- 10th Anti-Infectives Partnering and Deal-making Conference: **“Enabling Anti-Infective Drug Product Efforts across the Development Spectrum”** (2013)
- Department of Defense Biodefense Committee, National Academy of Sciences **“New Directions for Anti-Infectives: NIH Perspectives”** (2013)
- Homeland Security Program, Meade High School: **“Public Health Preparedness – NIH Perspectives”** (2013)
- Program for Emerging Leaders' Winter Workshop: **“Public Health Preparedness: Views from HHS NIH Perspectives”** (2013)
- Biomedical Advanced Research & Development Authority Industry Day: **“Goal 1: MCM Development & Manufacturing / NIH Perspectives”** (2012)
- Canadian Embassy: **“NIAID Opportunities for Researchers and Current Product Development Activities”** (2012)

- Dynamics of Preparedness Conference: **“High Priority Preparedness Research and its Support”** (2012)
- Chemical Science Roundtable, National Academy of Sciences: **“The Need for New Antibiotics”** (2012)
- NIAID Bottlenecks Workshop: **“Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases”** (2012)
- Georgian National Center for Disease Control and Public Health: **“NIAID’s Role in BioDefense and Emerging Infectious Diseases”** (2012)
- 10th Annual Biodefense Vaccines and Therapeutics Summit: **“Incentivizing Public and Private Partnership and Investments in R&D for MCMs and Anti-Infectives”** (2012)
- World Vaccine Congress: **“Enhancing Existing Vaccines, Developing Technologies for Biodefense Vaccines”** (2012)
- Food and Drug Administration Anti-Infective Drugs Advisory Committee: **“Pneumonic Plague & Public Health Needs”** (2012)
- Chem-Bio Core Capabilities, National Academy of Sciences: **“Core Capabilities in Biological Defense R&D at NIH”** (2012)
- BIO Biosecurity Conference: **“Innovative Strategies to Develop New Countermeasures,”** (2012)
- Centers for Disease Control & Prevention Anthrax Antitoxin and PEP Workshop: **“Anthrax Antibiotic PEP Duration when used in Combination with Anthrax Vaccine”** and **“Emerging Issues related to Potential Anthrax Vaccine PEP Utilization Strategies”** (2012)
- Life Science Summit: **“Beyond VCs and Wall Street: The Role of Government Agencies and Foundations as Fuel to the Life Science R&D engine”** (2011)
- 8th Anti-Infectives Partnering and Deal-Making Conference **“Novel Antiviral Host Based Targeting Influencing Drug Development”** (2011)
- Use of Chimpanzees in Biomedical and Behavioral Research Meeting, Institute of Medicine: **“The Role of Chimpanzees in BioDefense Research – NIH perspective”** (2011)
- 9th Annual Biodefense Vaccines & Therapeutics Summit: **“Government Technology Development and Translational Science Efforts”** (2011)
- Partnering for Global Health Forum, BIO: **“How to Access Non-Dilutive Funding”** (2011)
- BIO International Convention: **“NIAID Product Development” Lowering Risk with Program and Resources”** (2011)
- Advancing Regulatory Science for Medical Countermeasure Development Workshop, Institute of Medicine: **“What do the partners need?”** (2011)
- NIH-Industry Roundtable: Exploring New Uses for Abandoned and Approved Therapeutics: **“NIAID Product Development: Lowering Risk with Programs & Resources”** (2011)
- University of Texas A&M: **“NIAID Biodefense Research & Development Program”** (2011)
- Department of Defense USG Portfolio Managers Workshop: **“Projecting US Government Biodefense Medical Countermeasures Portfolio”** (2011)
- Preserving National Security: The Growing Role of the Life Sciences: **“NIAID**

- Programs & Priorities”** (2011)
- 6th Annual CBRNE Defense Conference: **“Development of Medical Countermeasures against Bioterrorism Threats”** (2011)
- North Carolina Biotechnology Center: **“Mechanisms to Enhance Development of Public Health Biomedical Products”** (2011)
- 5th Annual PHEMCE Stakeholders Workshop and BARDA Industry Day: **“HHS Medical Countermeasure Review: The Role of NIH”** (2011)
- CDC NBAS Task Force Innovative Information Sources Meeting: **“Innovative Information Sources Workgroup (random observation)”** (2010)
- National Academies Standing Committee on Biodefense: **“Obtaining Early Insight”** (2010)
- Animal Welfare and Scientific Research: 1985 – 2010: **“Infectious Diseases and Animal Models”** (2010)
- Hun School of Princeton Career Day: **“Physician / Scientist”** (2010)
- NBL/RBL Biodefense Network Meeting: **“HHS Medical Countermeasure Review”** (2010)
- National Biotechnology Center for Advanced Product Development Infrastructure Steering Committee meeting: **“NIAID Extramural Biodefense Facility Section”** (2010)
- NIH Scientific Management Review Board: **“NIAID Product Development Programs and Resources”** (2010)
- Interscience Conference on Antimicrobial Agent and Chemotherapy (ICAAC): **“NIAID Antimicrobial Stimulus Activities”** (2010)
- FDA/NIAID/IDSA Public Workshop: Antibacterial Resistance and Diagnostic Device and Drug Development Research for Bacterial Diseases: **“NIAID Antimicrobial Research Activities”** (2010)
- 8th Annual Biodefense Vaccines & Therapeutics Summit: **“NIAID Biodefense Opportunities and Funding”** (2010)
- Johnson & Johnson: **“NIAID BioDefense Program and Animal Rule”** (2010)
- BIO Convention: **“Public Private Partnerships for State of the Art Countermeasures”** (2010)
- National Academies of Science Drug Forum: **“NIAID Product Development”** (2010)
- World Vaccine Congress: **“Biodefense Opportunities at NIAID”** (2010)
- Pennsylvania Biotechnology Center: **“Product Development Resources through NIAID”** (2010)
- National Academies of Science Special Immunizations Workshop: **“Special Immunizations Program (SIP) / NIAID Perspectives”** (2010)
- Institute of Medicine Workshop: The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from Discovery through Approval: **“Opportunities for Enhancing Translation of Basic Science”** (2010)
- Life Science Action Summit: **“Infectious Disease: New Paradigms Defining 21st Century Medicine”** (2010)
- 5th Annual CBRNe Conference: **“Evaluating Post-Event Strategies for Civilian Threats”** (2010)
- Public Health and Emergency Medical Countermeasures Workshop: **“Basic Medical**

- Countermeasure Research & Early Development”** (2009)
- FDA / IDSA Respiratory Diagnostics Workshop: **“Detection of Anthrax and other Biothreat Agents”** (2009)
- Global Health Security Initiative Public Health Emergency Medical Countermeasures Workshop: **“Medical Countermeasures Programs on BioDefense, Radiological/Nuclear and Chemical Threats at the National Institute of Allergy and Infectious Diseases”** (2009)
- National Academy of Sciences, Department of Defense Chemical Biological Defense Science & Technology Review: **“NIAID Perspective on Animal Models for Assessing Countermeasures to Bioterrorism Agents”** (2009)
- NIAID Community Relations Program Workshop: **“NIAID BioDefense: In for the Long Haul”** (2009)
- FDA Smallpox Workshop: **“NIAID Perspective on Smallpox Medical Countermeasures”** (2009)
- University of California San Diego, Institute on Global Conflict and Cooperation Public Policy and Biological Threats Training Program: **“BioDefense Product Development”** (2009)
- Biomedical Advanced Research & Development Authority CBRN Medical Countermeasures Workshop 2009: **“Funding Mechanisms & roles in MCM Development”** (2009)
- University of Tennessee Regional Biocontainment Laboratory Ribbon Cutting Ceremony: **“Remarks”** (2009)
- 7th Annual BioDefense Vaccines and Therapeutics Conference: **“NIAID Biodefense Opportunities and Funding”** (2009)
- Seminar on Disease Control and Prevention in the Yangtze River Delta Region, Shanghai, China: **“Infectious Disease: Public Health goes Global”** (2009)
- World Vaccine Congress 2009: **“NIH BioDefense Research and Development Priorities and Programs”** (2009)
- New England Infectious Diseases and Biodefense Symposium: **“Infectious Disease: The Ultimate Darwinian Challenge”** (2009)
- 4th Annual CBRN Conference: **“Monitoring Long Term Sequellae and Countermeasure Side Effects Post CBRN Event”** (2009)
- Phacilitate Vaccine Forum Washington: **“Public Health Medical Countermeasures – NIH”** (2009)

CONGRESSIONAL TESTIMONY

- House Appropriations Subcommittee on Labor, Health, and Human Services, and Education: **Public Health Emergency Medical Countermeasure Enterprise Oversight** (February 27, 2014)
- House Homeland Security Subcommittee on Emerging Threats, Cybersecurity and Science and Technology: **Emerging Biological Threats & Public Health Preparedness** (July 22, 2008)

CURRENT COMMITTEE / WORKGROUP / TASKFORCE RESPONSIBILITIES

Federal

Executive Committee, NCATS
Pain, Common Fund, NIH
Tran-NIH Opioid Program
Data Sharing Working Group, NIH
Improving the Efficiency of Clinical Trials for Drug Development Workgroup, ASPE,
HHS

T42 Search Committees

Director, Radiation and Nuclear Countermeasures Research Program, DAIT, NIAID
Director, Integrated Research Facility, NIAID (Committee Chair)

Other

Steering Committee, Clinical Trials Transformation Initiative

FORMER COMMITTEE / WORKGROUP TASKFORCE RESPONSIBILITIES

NIH

Executive Committee, NIAID
NIH Coordinating Committee for NEIDL Risk Assessment
Nano-Biodefense Working Group of Nano Taskforce, NIH
Clinical and Translational Science Awards Consortium Steering Committee, NIH
Roadmap
Co-Director, Clinical and Translational Science Award Program, NIH Roadmap
Molecular Libraries and Imaging Implementation Group (MLIIG), NIH Roadmap
Molecular Libraries Screening Centers Network Project Team, NIH Roadmap
Trans-NIH Biodefense Research Coordinating Committee
NIH/FDA Partnership, Drug Rescue and Repurposing Workgroup
NIH/FDA Partnership, Culture Subcommittee
Clinical Research Working Group, DMID/NIAID
R34 Review Committee, DMID/ NIAID
BioDefense Working Group, NIAID
Regional Translational Research Centers Implementation Group, NIH Roadmap

Department of Health and Human Services

Senior Advisor, Public Health and Emergency Medical Countermeasures Enterprise
(PHMCE) Seniors Council
PHEMCE Executive Committee (NIH voting member)
PHEMCE Strategy and Implementation Plan Steering Committee
National Preparedness and Response Science Board (NPRSB, formerly the National
Biodefense Science Board) Selection Committee
PHEMCE Portfolio Advisory Committee
HHS National Health Security Strategy Working Group (NIH rep)
HHS-Centers of Innovation for Advance Development & Manufacturing Steering
Committee
HHS Ebola Medical Countermeasures Senior Steering Group
Zika Vaccine Development Interagency Working Group
HHS Zika Medical Countermeasures Leadership Group
HHS National Biodefense Strategy Working Group
PHEMCE Medical Countermeasures Operational Planning Working Group
Medical Countermeasures Advisory Board (HHS)
Countermeasures Steering Committee
Anthrax Integrated Project Team
Botulism Integrated Project Team
Smallpox Integrated Project Team
Smallpox Vaccine Strategy Workgroup
rPA Project Coordination Team
Anthrax Therapeutics Project Coordination Team
Implementation Team for Pandemic & All Hazards Preparedness Act / Homeland
Security Presidential Directive – 21
Co-Chair, BARDA Workgroup for Pandemic & All Hazards Preparedness Act
Implementation
Co-Chair, Biologicals Working Group, Public Health and Emergency Medical
Countermeasures Enterprise
Integrated Risk Management Committee
HHS CBRN Strategy and Implementation Planning Working Group
Steering and Integration Group, Weapons of Mass Destruction Medical Countermeasures
Subcommittee
Co-Chair, Biologicals Working Group, Weapons of Mass Destruction Medical
Countermeasures Subcommittee
Advisory Council on Elimination of Tuberculosis (*ex officio*)

Title 42 Search Committees

Chief Medical Officer, NIEHS
Associate Director, Clinical Research, DMID/NIAID
Director, Therapeutics for Rare and Neglected Diseases, NCATS (Committee Chair)
Director, Office of Biodefense and Surety, NIAID
Chief, Bacteriology and Mycology Branch, DMID/NIAID (Committee Chair)
Director, Influenza Division, BARDA

Director, CBRN Division, BARDA
Scientific Director, NCATS

Trans-Federal & other Federal Agencies

Pandemic Prediction and Forecasting Science and Technology Working Group (NSTC)
Federal Interagency Review Panel on High-Containment Laboratory Space
BSAT sub-IPC on FESAP/FTAC Implementation (National Security Staff)
Fast Track Action Committee on Select Agent Regulations, OSTP
Fast Track Action Committee on Bio, OSTP
Committee on Homeland and National Security (CHNS), OSTP (NIH rep)
Subcommittee on Biological Defense R&D (BDRD), CHNS/OSTP
Federal Interagency Review Panel on High-Containment Laboratory Space
Interagency BioRisk Management Working Group, BDRD/CHNS/OSTP
DHS MTA 2.0 Anthrax Workgroup
Pre-Event Anthrax Vaccine Distribution Federal Interagency Working Group
Transformational Medical Technologies Initiative Overarching Integrated Process Team,
Department of Defense
Militarily Critical Technologies List, Department of Defense
Special Advisor, Chemical & Biological Warfare Defense Panel, Threat Reduction
Advisory Committee, Department of Defense
Interagency Biological Risk Assessment Working Group, DHS
Biochem 20/20, Defense Intelligence Agency / Central Intelligence Agency
Integrated National Biodefense MCM Portfolio Advisory Committee
Trans-Federal National Biotechnology Center for Advanced Product Development
(NBCAPD) Infrastructure Steering Committee, Department of Defense
Chemical and Biological Warfare Defense Panel, Threat Reduction Advisory Council,
Department of Defense
Enhanced Threat Agent Working Group, Department of Homeland Security
National Biodefense Analysis and Countermeasures Center Scientific Advisory Group,
Department of Homeland Security
Federal Interagency Biological Concept of Operations Plan
Anthrax Preparedness sub-PCC, Homeland Security Council
Pre-Event Anthrax Vaccine Federal Interagency Working Group
Homeland Security S&T Policy Task Force
Homeland Security Council / National Security Council Sub-Policy Coordinating
Committee - Preparation for World Health Assembly-64

Other

Global Coordination Mechanism for Research and Development, WHO (2017)
Health and Security Forum: Health on the Front Lines, Center for Strategic and
International Studies (2017)
Scientific Advisory Committee, Coalition for Epidemic Preparedness Innovations (since

2016)

Global Virome Project Steering Committee (2016-2017)

Joint Oversight Committee, CARB-X (2016-2017)

Chair, World Health Organization Scientific and Technical Advisory Committee for Ebola (2014-2017)

World Health Organization Ebola Science Committee (2014-2017)

World Health Organization Filovirus Therapeutics Working Group (2014-2017)

CABP-ABSSSI Project Team, Biomarkers Consortium of the Foundation for the National Institutes of Health (2010-2017)

Forum on Medical and Public Health Preparedness for Catastrophic Events, Institute of Medicine (2007-2017)

Biological Emergency Advisory Team

Prior to Federal Employment

Co-Chair, 8th International Antibacterial Drug Development & Discovery Summit

Infectious Disease Exploratory Advisory Board, Wyeth Pharmaceuticals

Infectious Disease Therapeutic Area Leadership Team, Wyeth Pharmaceuticals

Infectious Disease Licensing Team, Wyeth Pharmaceuticals

Chair, Research Management Committee, AMRI Collaboration, Dupont Pharma

Chair, Research Management Committee, Phytomyco Collaboration, Dupont Pharma

Chair, Research Management Committee, BioLeads Collaboration, Dupont Pharma

Chair, Institutional Biosafety Committee, Dupont Pharma

PRT – Medical, Dupont Pharma

IACUC, Dupont Pharma

Research Management Committee, Scriptgen Collaboration, Dupont Pharma

Residency Program Review Committee, Department of Pathology, University of Virginia

Director, Pathology Research Seminar series, University of Virginia

Institutional Biosafety Committee, University of Virginia

Pathology Strategic Planning Committee, University of Virginia

Hospital Epidemiology Committee, University of Virginia

Committee on Microbiological Safety, Harvard Medical School

Computer Committee, Department of Pathology, Brigham & Women's Hospital

Chair, Executive Committee, New England Pathology Resident's Society

TECHNICAL & FORMAL PROGRAMMATIC REVIEWS

Milestone Decision Authority Advisory Board, BARDA/HHS (2017)

External Reviewer, Global Health Innovation Technology Fund (2013-present)

Reviewer, Chemical and Biological Defense Program, DOD (2013)

Reviewer, Chemical and Biological Defense Program, DOD (2012)

Technical Reviewer, National Security Science and Engineering Faculty Fellowship, USAF/DOD (2009)

Chair, Review Panel, Transformational Medical Technologies Initiative, DOD (2008)

Reviewer, 3rd Annual Chemical and Biological Division Program Review, DHS (2007)

Source Selection Board, Transformational Medical Technologies Initiatives, DOD (2007)
Reviewer, 2nd Annual Biological Countermeasures Program Review, DHS (2006)
Technical Reviewer, Accelerated Manufacture of Proteins Program, DARPA (2006)

JOURNAL REVIEWER EXPERIENCE

Human Vaccines and Immunotherapeutics
Health Security
International Journal of Bacteriology
New England Journal of Medicine
Microbial Biotechnology
Intensive Care Medicine Experimental
Biosecurity and Bioterrorism
American Journal of Tropical Medicine and Hygiene
Human Vaccines
Clinical Chemistry

EDITORIAL EXPERIENCE

Guest Editor for Thematic Issue: Bioterrorism Research, Microbial Biotechnology, Sept
2012

UNITED STATES GOVERNMENT SECURITY CLEARANCE

Top Secret – 2005
Top Secret with SCI – 2010
Top Secret with SCI - 2017 (current)

TEACHING EXPERIENCE

Instructor, Microbial Pathogenesis, Department of Microbiology, University of Virginia
Medical School (1995 - 1998)
Lecturer, Pathology, University of Virginia Medical School (1995 - 1998)
Instructor, Special Topics in Immunology, Viral Pathogenesis, Department of
Microbiology, University of Virginia Medical School (1993)
Instructor, Virology, Department of Microbiology, University of Virginia Medical School
(1991 - 1994)
Instructor, Pathophysiology of Infectious Disease, Harvard Medical School (1986 - 1991)
Instructor, Gastrointestinal Pathophysiology, Harvard Medical School (1986)
Laboratory Assistant, Medical Microbiology, Duke University School of Medicine (1981
– 1983)
Teaching Assistantship, Department of Chemistry, California Institute of Technology
(1979)

MEDICAL LICENSURE

Massachusetts: 1985 – 1991

Virginia: 1991 - 1998

PAST RESEARCH GRANT SUPPORT

GenBio licensing agreement for use of EBV recombinant protein as immunodiagnostic reagent

National Institutes of Health P01, Epidemiological, Molecular, and Immunological Pathogenesis of Epstein - Barr virus Positive Hodgkin's Disease, 8/1/97 - 7/31/01, total direct costs: **\$319,825** (out of a total program cost of \$7,800,000) - voluntarily terminated 6/98

Markey Scholar Award #91-52, Characterization of Human T cell mediated immunity to Epstein-Barr virus, 7/1/91 - 6/30/96, total direct costs **\$540,000**.

University of Virginia Cancer Center Developmental Funds, 1/1/92 - 12/31/92, total direct costs **\$48,000**.

Markey Scholar Award #89-24, Characterization of Human T cell mediated immunity to Epstein-Barr virus, 7/1/89 - 6/30/91, total direct costs **\$103,000**.

Life Science Research Foundation Fellowship, Characterization of the EBV transforming gene, LMP, 7/1/87 - 6/30/89, total direct costs **\$70,000**.

OUTSIDE PROFESSIONAL ACTIVITIES

F1000 Faculty Member, Pharmacology and Drug Discovery: Antimicrobial Agents (2011- present) - >20 post publication reviews

Specialist Reviewer, Appraisal (1988 - 2002) ~100 science book reviews

Science Mentor, Boston Science Museum (1997 - 1999)

PUBLICATIONS

Invited Reviews & Commentary

- Kurilla, MG.** 2016. Ebola: A View from the National Institute of Allergy and Infectious Diseases. Proceedings of a Workshop: The Ebola Epidemic in West Africa. The National Academies Press, Washington, DC.
- Outterson, K, JH Rex, T Jinks, P Jackson, J Halliman, S Karp, DT Hung, F Franceschi, T Merkeley, C Houchens, DM Dixon, **MG Kurilla**, R Aurigemma, and J Larsen. 2016. Accelerating global innovation to address antibacterial resistance: introducing CARB-X. *Nat Rev Drug Discov* **15**:589-90.
- Kurilla, MG.** 2014. Containing infectious disease. *Pathog Dis.* **71**:94-5.
- Coller-Monarez, C, SL Groseclose, **MG Kurilla**, and JM Berg. 2013. High Priority Preparedness Research and its Support. *J Public Health Manag Pract.* 19:S9-S11.
- Kurilla, M.** 2011. Animal Models Facilitate Rapid Responses to Emerging Infectious Diseases. *ILAR J* **52S**:501-506.
- Kurilla, MG.** 1993. Target antigens of Epstein-Barr virus (EBV) and the implications for immune control of EBV-associated disease. *Sem Virol* **4**:95-100.

Peer Reviewed Manuscripts

- Patterson, A, K Fennington, R Bayha, D Wax, R Hirschberg, N Boyd, **M Kurilla**. 2014. Biocontainment laboratory risk assessment: perspectives and considerations. *Pathog Dis.* **71**:102-8.
- Hendricks KA, ME Wright, SV Shadomy, JS Bradley, MG Morrow, AT Pavia, E Rubinstein, JE Holty, NE Messonnier, TL Smith, N Pesik, TA Treadwell, WA Bower, **Workgroup on Anthrax Clinical Guidelines**. 2014. Centers for Disease Control and Prevention Expert Panel Meetings on prevention and treatment of anthrax in adults. *Emerg Infect Dis* 20(2) [only available online: http://wwwnc.cdc.gov/eid/article/20/2/13-0687_intro]
- Talbot GH, JH Powers, TR Fleming, JA Siuciak, J Bradley, H Boucher, **CABP-ABSSSI Project Team**. 2012. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. *Clin Infect Dis.* **55**:1114-21.
- Bobkova, EV, YP Yan, DB Jordan, **MG Kurilla**, DL Pompliano. 2003. Catalytic properties of mutant 23S ribosomes resistant to oxazolidinones. *J Biol Chem* **278**:9802-9807.

- Barbosa MD, S Lin, JA Markwalder, JA Mills, JA DeVito, CA Teleha, V Garlapati C Liu, A Thompson, GL Trainor, **MG Kurilla**, DL Pompliano. 2002. Regulated expression of the *Escherichia coli* lepB gene as a tool for cellular testing of antimicrobial compounds that inhibit signal peptidase I *in vitro*. *Antimicro Agents Chemo* **46**:3549-3554.
- Barbosa MD, HO Ross, MC Hillman, RP Meade, **MG Kurilla**, DL Pompliano. 2002. A multitarget assay for inhibitors of membrane-associated steps of peptidoglycan biosynthesis. *Anal Biochem.***306**:17-22.
- Zhang, Y, F Yang, YC Kao, **MG Kurilla**, DL Pompliano, IB Dicker. 2002. Homogenous assays for *Escherichia coli* DnaB-stimulated DnaG primase and DnaB helicase and their use in screening for chemical inhibitors. *Anal Biochem* **304**:174-179.
- Yang, F, IB Dicker, **MG Kurilla**, DL Pompliano. 2002. PolC-type polymerase III of *Streptococcus pyogenes* and its use in screening for chemical inhibitors. *Anal Biochem* **304**:110-116.
- Barbosa, MD, G Yang, J Fang, **MG Kurilla**, DL Pompliano. 2002. Development of a whole-cell assay for peptidoglycan biosynthesis inhibitors. *Antimicro Agents Chemo* **46**:943-946.
- Patel, U, YP Yan, J Hobbs, J Kaczmarczyk, AM Slee, DL Pompliano, **MG Kurilla**, EV Bobkova. 2001. Oxazolidinone mechanism of action: Inhibition of the first peptide bond formation. *J Biol Chem* **276**:37199-37205.
- Lui, J, PA Feldman, JS Lippy, E Bobkova, **MG Kurilla**, TD Chung. 2001. A scintillation proximity assay for RNA detection. *Anal Biochem* **289**:239-245.
- Steigerwald-Mullen, P, **MG Kurilla**, TJ Braciale. 2000. Type 2 cytokines predominate in the human CD4+ T-lymphocyte response to Epstein-Barr virus nuclear antigen 1. *J Virol* **74**:6748-6759.
- Munz, C, KL Bickman, M Subklewe, ML Tsang, A Chahroudi, **MG Kurilla**, D Zhang, M O'Donnell, RM Steinman. 2000. Human CD4+ T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. *J Exp Med* **191**:1649-1660.
- Jin, X, MA Demoitie, SM Donahue, GS Ogg, S Bonhoeffer, WM Kakimoto, Gillespie, PA Moss, W Dyer, **MG Kurilla**, SR Riddell, J Downie, JS Sullivan, AJ McMichael, C Workman, DF Nixon. 2000. High frequency of cytomegalovirus-specific cytotoxic T-effectors in HLA-A*0201-positive subjects during multiple viral coinfections. *J Infect Dis* **181**:165-75.
- Subklewe, M, A Chahroudi, K Bickman, M Larsson, **MG Kurilla**, N Bhardwaj, RM Steinman. 1999. Presentation of Epstein-Barr virus latency antigens to CD8+, interferon- γ -secreting, T lymphocytes. *J Immunol* **29**:3995-4001.
- Subklewe, M, A Chahroudi, A Schmaljohn, **MG Kurilla**, N Bhardwaj, RM Steinman. 1999.

- Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus. *Blood* **94**:1372-1381.
- Webb, DJ, J Wen, LR Karns, **MG Kurilla**, and SL Gonias. 1998. Localization of the binding site for transforming growth factor- β in human β_2 -macroglobulin to a 20-kDa peptide which also contains the bait region. *J Biol Chem* **273**:13339-13346.
- Levitsky, V, QJ Zhang, J Levitskaya, **MG Kurilla**, and MG Masucci. 1997. Natural variants of the immunodominant HLA A11-restricted CTL epitope of the EBV nuclear antigen-4 are nonimmunogenic due to intracellular dissociation from the MHC class I-peptide complexes. *J Immunol* **159**:5383-5390.
- Blake, N, S Lee, I Redchenko, W Thomas, N Steven, A Leese, P Steigerwald-Mullen, **MG Kurilla**, L Frappier, and A Rickinson. 1997. Human CD8⁺ T cell responses to Epstein-Barr virus EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. *Immunity* **7**:791-802.
- Khanna, R, SR Burrows, PM Steigerwald-Mullen, DJ Moss, **MG Kurilla**, and L Cooper. 1997. Targeting Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) through the class II pathway restores immune recognition by EBNA1-specific CD4⁺ cytotoxic T lymphocytes: An evidence for HLA DM-independent processing. *Internat Immunol* **9**:1537-1543.
- Shi, Y, KD Smith, **MG Kurilla**, and CT Lutz. 1997. Cytotoxic CD8⁺ T cells recognize EBV antigen but poorly kill autologous EBV-infected B lymphoblasts: Immunodominance is elicited by a peptide epitope that is presented at low levels in vitro. *J Immunol* **159**:1844-1852.
- Steven, NM, NE Annels, A Kumar, AM Leese, **MG Kurilla**, and AB Rickinson. 1997. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. *J Exp Med* **185**:1605-1617.
- Kurilla, MG**. 1997. Dominant selection in the absence of selectable markers during vaccinia virus recombination. *Biotechniques* **22**:906-910.
- Frisa, T, Q-J Zhang, J Levitskaya, M Coram, **MG Kurilla**, and MG Masucci. 1996. Defective presentation of MHC class I-restricted cytotoxic T-cell epitopes in Burkitt's lymphoma cells. *Int J Cancer* **67**:1-8.
- White, CA, SM Cross, **MG Kurilla**, BM Kerr, C Schmidt, IS Misko, R Khanna, and DJ Moss. 1996. Recruitment during infectious mononucleosis of CD3⁺CD4⁺CD8⁺ virus-specific cytotoxic T cells which recognize Epstein-Barr virus lytic antigen BHRF1. *Virology* **219**:489-49.
- Khanna, R, SR Burrows, PM Steigerwald-Mullen, SA Thompson, **MG Kurilla**, and DJ Moss.

1995. Isolation of Epstein-Barr virus nuclear antigen 1-specific cytotoxic T lymphocytes from healthy seropositive individuals: Implications for viral persistence and tumor surveillance. *J Exp Med* **214**:633-637.
- Levitskaya, J, M Coram, V Levitsky, S Imreh, PM Steigerwald-Mullen, G Klein, **MG Kurilla**, and MG Masucci. 1995. The internal repeat region of the Epstein-Barr virus nuclear antigen-1 is a cis-acting inhibitor of antigen processing and MHC class I restricted presentation. *Nature* **375**:865-868.
- Kurilla, MG**, T Heineman, L Davenport, E Kieff, and L Hutt-Fletcher. 1995. Characterization of a novel glycoprotein expressed by the BDLF3 open reading frame of Epstein-Barr virus. *Virology* **209**:108-121.
- Argaet, VP, CW Schmidt, SR Burrows, **MG Kurilla**, DL Doolan, A Suhrbier, DJ Moss, E Kieff, TB Sculley, and IS Misko. 1994. Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. *J Exp Med* **180**:2335-2340.
- Kurilla, MG**, S Swaminathan, RM Welsh, E Kieff, and RR Brutkiewicz. 1993. Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. *J Virol* **67**:7673-7676.
- Lee, SP, WA Thomas, RJ Murray, F Khanim, S Kaur, LS Young, M Rowe, **MG Kurilla**, AB Rickinson. 1993. HLA A2.1-restricted cytotoxic T cells recognising a range of Epstein-Barr virus isolates through a defined epitope in the latent membrane protein LMP2. *J Virol* **67**:7428-7435.
- Brooks, JM, RJ Murray, WA Thomas, **MG Kurilla**, and AB Rickinson. 1993. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. *J Exp Med* **178**:879-887.
- Gavioli, R, **MG Kurilla**, PO deCampos-Lima, LE Wallace R Dolcetti, RJ Murray, AB Rickinson, MG Masucci. 1993. Multiple HLA A11 restricted CTL epitopes of different immunogenicity in the Epstein-Barr virus (EBV) encoded nuclear antigen-4 (EBNA4). *J Virol* **67**:1572-1578.
- Lear, AL, M Rowe, **MG Kurilla**, S Lee, S Henderson, E Kieff, and AB Rickinson. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into lytic cycle. *J Virol* **66**:7461-7468.
- Murray, RJ, **MG Kurilla**, JM Brooks, WA Thomas, M Rowe, E Kieff, and AB Rickinson. 1992. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies. *J Exp Med* **176**:157-168.
- Khanna, R, SR Burrows, **MG Kurilla**, CA Jacob, IS Misko, TB Sculley, E Kieff, DJ Moss. 1992. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant

- vaccinia: Implications for vaccine development. *J Exp Med* **176**:169-176.
- Gavioli, R, PO DeCampos-Lima, **MG Kurilla**, E Kieff, G Klein, and MG Masucci. 1992. Recognition of the Epstein-Barr virus nuclear antigens EBNA-4 and EBNA-6 by HLA A11 restricted cytotoxic T-lymphocytes. *Proc Natl Acad Sci USA* **89**:5862 - 5866.
- Khanna, R, CA Jacob, SR Burrows, **MG Kurilla**, E Kieff, IS Misko, TB Sculley, and DJ Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cell. *Immunology* **74**:504-510.
- Wang, F, S-F Tsang, **MG Kurilla**, JC Cohen, and E Kieff. 1990. Epstein-Barr virus nuclear antigen 2 transactivates the latent membrane protein (LMP1). *J Virol* **64**:3407-3416.
- Murray, RJ, **MG Kurilla**, HM Griffin, JM Brooks, M Mackett, JR Arrand, M Rowe, SR Burrows, DJ Moss, E Kieff, and AB Rickinson. 1990. Human cytotoxic T cell responses against Epstein-Barr virus nuclear antigens demonstrated using recombinant vaccinia viruses. *Proc Natl Acad Sci USA* **87**:2906-2910.
- Fresco, L, **MG Kurilla**, and JD Keene. 1987. Rapid inhibition of processing and assembly of small nuclear ribonucleoproteins after infection with vesicular stomatitis virus. *Mol Cell Biol* **7**:1148-1155.
- Kurilla, MG**, H Stone, and JD Keene. 1985. The sequence of the leader RNA and start of the nucleocapsid gene of Newcastle disease virus. *Virology* **145**:203-212
- Kurilla, MG**, C Cabradilla, B Holloway, and JD Keene. 1984. Nucleotide sequence and host La protein interactions with the leader RNA of rabies virus. *J Virol* **50**:773-778.
- Chambers, JC, **MG Kurilla**, and JD Keene. 1983. Association between the 7S RNA and the lupus La protein varies among cell types. *J Biol Chem* **258**:11438-11441.
- Wilusz, J., **MG Kurilla**, and JD Keene. 1983. A host protein (La) binds to a unique species of minus sense leader RNA during the replication of vesicular stomatitis virus. *Proc Natl Acad Sci USA* **80**:5827-5831.
- Kurilla, MG** and JD Keene. 1983. The leader RNA of vesicular stomatitis virus is bound by a cellular protein reactive with anti La lupus antibodies. *Cell* **34**:837-845.
- Kurilla, MG**, H Piwnica-Worms, and JD Keene. 1982. Rapid and transient localization of the leader RNA of vesicular stomatitis virus in the nuclei of infected cells. *Proc Natl Acad Sci USA* **79**:5240-5244.
- Hazi, A. U., TN Rescigno, and **M Kurilla**. 1981. Cross sections for resonant vibrational excitation of molecular nitrogen by electron impact. *Phys Rev A* **23(3)**:1089-1099.

Schaefer, WP, BT Huie, **MG Kurilla**, and SE Ealick. 1980. Oxygen-carrying cobalt complexes. 10. Structures of N, N'-ethylenebis (3-tert-butylsalicylideniminato) cobalt (II) and its monomeric dioxygen adduct. *Inorg Chem* **19**:340- 344.

Kurilla, MG and WP Schaefer. 1979. The structure of mu-amido-hexaamine-di-mu-hydroxo- dicobalt (III) tribromide. *Acta Cryst* **B35**:3008-3010.

Book Chapters

Glowinski, IB, JB Bernstein, and **MG Kurilla**. 2011. How Basic Research is Translated into Applied Countermeasures: Role of the National Institute of Allergy and Infectious Diseases. *Encyclopedia of Bioterrorism Defense*, 2nd ed. Wiley-Blackwell.

Kieff, E, F Wang, M Birkenbach, J Cohen, J Sample, B Tomkinson, S Swaminathan, R Longnecker, A Marchini, J Mannick, S-F Tsang, C Sample, and **M Kurilla**. 1991. Molecular biology of lymphocyte transformation by Epstein-Barr virus. **In** *Origins of Human Cancer: A Comprehensive Review*. Eds. H. H. Hiatt, J. D. Watson, and J. D. Winsten. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.

Keene, JD, **MG Kurilla**, J Wilusz, and JC Chambers. 1984. Interactions between cellular La protein and leader RNAs. **In** *The Replication of Negative Strand Viruses*. Eds. D. H. L. Bishop and R. W. Compans. Elsevier North Holland, Inc. New York.